FANCF methylation contributes to chemoselectivity in ovarian cancer

Slides:



Advertisements
Similar presentations
Alterations in the Cell Cycle and Gene Mutations that Cause Cancer
Advertisements

By Janet Soper and its Effects in Breast Cancer and Ovarian Cancer.
BRCA1 Breast Cancer 1, Early Onset Simple gene, or breast/ovarian cancer’s best friend? By:Courtney Abshier.
BRCA1 The First Breast Cancer Gene Presentation By Liz Mosley.
BRCA Genes Dallas Henson.
BRCA Mutations and Breast Cancer Ruth Phillips and Patty Ashby.
BRCA1: Tumor Suppression and Breast Cancer A breast cancer cell dividing.
Genetics of Cancer Genetic Mutations that Lead to Uncontrolled Cell Growth.
The Cell Cycle and Cancer AP Biology. Cell Cycle Numerous genes control the cell cycle They regulate the progression through checkpoints. A sensor detects.
BRCA2: Breast Cancer Susceptibility Gene 2 Lindy Behrend March 4, 2003.
Genetics of Cancer Genetic Mutations that Lead to Uncontrolled Cell Growth.
Tumor Suppressor Gene Involved in Breast and Ovarian Cancers SCIENCE96/gene.cgi?BRCA1.
IN CANCER MOLECULAR DETECTION. WHAT DO THEY DETECT? Specific proteins Expression of certain genes Mutations Epigenetic Changes.
Have a positive role in cell division Have a negative role in cell division Have a role in the maintenance of DNA integrity Genes altered in cancer typically:
New players in the BRCA1-dependent
Control of Gene Expression
GENETIC BASIS OF CANCER
The Genetic Basis of Cancer
Targeting the DNA Damage Response in Cancer
breast cancer 2, early onsetpro What does this protein make up or do?
Figure: Caption: The cell cycle is controlled at several checkpoints, including one at the G2/M transition, and another in late G1 phase before.
Alterations in the Cell Cycle and Gene Mutations that Cause Cancer
FANCD2: Fanconi Anemia and Cancer
BRCA1 Breast Cancer.
Tumor Promoting Inflammation
Concept 18.5: Cancer results from genetic changes that affect cell cycle control The gene regulation systems that go wrong during cancer are the very same.
Felix Dietlein, Lisa Thelen, H. Christian Reinhardt  Trends in Genetics 
B lymphocytes produce antibodies.
Chk1 and Chk2 kinases in checkpoint control and cancer
The BRCA1 suppressor hypothesis: An explanation for the tissue-specific tumor development in BRCA1 patients  Stephen J Elledge, Angelika Amon  Cancer.
George-Lucian Moldovan, Alan D. D'Andrea  Cancer Cell 
Methed-Up FOXOs Can't In-Akt-ivate
SMARCAD1 Phosphorylation and Ubiquitination Are Required for Resection during DNA Double-Strand Break Repair  Sharmistha Chakraborty, Raj K. Pandita,
Origin of Chromosomal Translocations in Lymphoid Cancer
Volume 10, Issue 2, Pages (August 2006)
Volume 137, Issue 2, Pages (May 2015)
RNA Processing and Genome Stability: Cause and Consequence
Jennifer L. Rizzo, Jessica Dunn, Adam Rees, Thomas M. Rünger 
Nat. Rev. Nephrol. doi: /nrneph
The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
Radiation-sensitive severe combined immunodeficiency: The arguments for and against conditioning before hematopoietic cell transplantation—what to do? 
Volume 3, Issue 4, Pages (April 2003)
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
ATM Creates a Veil of Transcriptional Silence
BRCA1 cooperates in the Fanconi anemia/BRCA1 pathway.
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Andrew J. Deans, Stephen C. West  Molecular Cell 
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
DNA Double-Strand Breaks Come into Focus
Proteins Kinases: Chromatin-Associated Enzymes?
Elanor N. Wainwright, Paola Scaffidi  Trends in Cancer 
Andrew N. Blackford, Stephen P. Jackson  Molecular Cell 
A Histone Code for Chromatin Assembly
Complicated Tails: Histone Modifications and the DNA Damage Response
Epigenome Maintenance in Response to DNA Damage
Specific Tumor Suppressor Genes
Initiating Cellular Stress Responses
Biology of hereditary breast and ovarian cancer (HBOC)
At Loose Ends: Resecting a Double-Strand Break
DNA Damage and Checkpoint Pathways
Are Mouse Telomeres Going to Pot?
Chromatin Modifications and Their Function
ATMIN: A New Tumor Suppressor in Developing B Cells
TGF-β Pathway Inhibition Signals New Hope for Fanconi Anemia
Tenets of PTEN Tumor Suppression
Epigenetics.
Anthony N. Imbalzano, Stephen N. Jones  Cancer Cell 
PTEN and p53: Who will get the upper hand?
Volume 3, Issue 4, Pages (April 2003)
Presentation transcript:

FANCF methylation contributes to chemoselectivity in ovarian cancer Olufunmilayo I Olopade, Minjie Wei  Cancer Cell  Volume 3, Issue 5, Pages 417-420 (May 2003) DOI: 10.1016/S1535-6108(03)00111-9

Figure 1 The Fanconi anemia/BRCA pathway and inactivation of BRCA1 in breast/ovarian cancer A: FANCD2 protein functions at the intersection of two signaling pathways. In response to ionizing radiation-mediated double-strand breaks (DSB), ATM phosphorylates the NBS1 protein. Phosphorylation of NBS1 is required for FANCD2 phosphorylation at serine 222 (S222), leading to activation of an S phase checkpoint. In response to DNA damage, the FA complex mediates the Ub of FANCD2 at lysine 561. Activated FANCD2 is translocated to chromatin and DNA repair foci, which contain the BRCA1 protein and BRCA2/FANCD1 protein complex. BRCA2/FANCD1 binds to RAD51 and to DNA, promoting a DNA repair response. The Ub-FANCD2 also colocalizes with NBS-MRE11-RAD50 complex in DNA damage nuclear foci. B: The mechanism of inactivation of BRCA1 in breast/ovarian cancer. Hypermethylation of the BRCA1 promoter was detected in sporadic breast and ovarian cancer samples with proportions ranging from 11% to 31% and from 5% to 15%, respectively. This model shows that promoter methylation can serve as a first hit in the BRCA1 and FANCF genes just as inherited mutation can serve as a first hit in the BRCA1 and BRCA2 genes. In cases where the first copy is methylated, the second copy may be inactivated by LOH or methylation. Cancer Cell 2003 3, 417-420DOI: (10.1016/S1535-6108(03)00111-9)

Figure 2 The heterogeneity of DNA methylaiton and gene expression In cancer, the dynamics of genetically and epigenetically mediated loss of gene function are very different. The results of the progressive and heterogeneous methylation are an increasing degree of transcriptional loss and a variable decrease in protein production in individual cells of tumor. Cancer Cell 2003 3, 417-420DOI: (10.1016/S1535-6108(03)00111-9)